MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Sells 224,319 Shares of Kenvue Inc. (NYSE:KVUE)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lowered its stake in Kenvue Inc. (NYSE:KVUE) by 12.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,632,584 shares of the company’s stock after selling 224,319 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Kenvue were worth $34,578,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in KVUE. Leo Wealth LLC raised its position in Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares during the last quarter. Alerus Financial NA raised its holdings in Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after buying an additional 491 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its position in Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after buying an additional 492 shares during the period. Kiley Juergens Wealth Management LLC grew its holdings in Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after acquiring an additional 500 shares during the last quarter. Finally, Wolff Wiese Magana LLC increased its position in Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after acquiring an additional 501 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent research reports. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Bank of America upped their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their price target for the company from $21.00 to $26.00 in a research note on Monday, January 6th. JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Stock Performance

Shares of KVUE stock opened at $20.75 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The firm has a 50 day moving average of $22.26 and a 200-day moving average of $21.74. The company has a market cap of $39.77 billion, a price-to-earnings ratio of 37.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.31 earnings per share. On average, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.